Collegium Pharmaceutical, Inc.COLL

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · collegiumpharma.com

Collegium Pharmaceutical, Inc. is a Massachusetts-based biopharmaceutical company delivering medicines for pain and central nervous system conditions: a responsible pain management portfolio of Xtampza ER (abuse-deterrent oxycodone), Nucynta ER/IR (tapentadol), Belbuca (buprenorphine buccal film) and Symproic, plus a growing ADHD/neuropsychiatry business built on Jornay PM and AZSTARYS. The company will relocate its headquarters from Stoughton to One Lincoln in downtown Boston in Q1 2027.

Key ratios

Operating cash flow growth

62.1%TTM

2025 60.7%2024 -25.4%2023 121.2%

EPS growth

33.2%TTM

2025 -6.6%2024 43.6%

FCF / Sales

40.8%TTM

2025 42.0%2024 32.2%2023 48.4%

Net margin

5.9%TTM

2025 8.1%2024 11.0%2023 8.5%

ROA

5.8%TTM

2025 7.3%2024 8.9%2023 9.5%

ROE

17.6%TTM

2025 23.7%2024 32.6%2023 24.7%

Revenue growth

14.3%TTM

2025 23.6%2024 11.4%2023 22.2%

Recent news

Collegium to Participate in Upcoming Investor Conferences 2026-09-08 · GlobeNewswire Collegium Announces $50 Million Accelerated Share Repurchase Program 2026-08-13 · GlobeNewswire Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress 2026-08-06 · GlobeNewswire Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026 2026-07-23 · GlobeNewswire Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston 2026-07-20 · GlobeNewswire

Track COLL in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer